Rob Hershberg, HilleVax CEO
August 15, 2023 07:11 AM EDTUpdated 01:16 PM
R&D

Take­da spin­out Hill­e­Vax de­lays PhI­Ib norovirus topline da­ta un­til mid-2024 over pro­cess­ing lo­gis­tics

Katherine Lewin

News Reporter

Take­da spin­out Hill­e­Vax has de­layed topline da­ta from its Phase IIb norovirus vac­cine tri­al un­til mid-2024, the com­pa­ny an­nounced Mon­day in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times